Balchem (BCPC) Stock Price & Analysis
BCPC Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- MXN 101.51B
- Enterprise Value
- MXN 5.36B
- Total Cash (Recent Filing)
- MXN 66.26M
- Total Debt (Recent Filing)
- MXN 142.44M
- Price to Earnings (P/E)
- 31.8
- Beta
- N/A
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- 26.4
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Margin Expansion
Improving gross, operating, and net margins indicate stronger operating efficiency and a favorable earnings profile. If maintained, this profitability gives Balchem more capacity to fund product development, absorb cost pressure, and convert segment growth into durable earnings over the next several quarters.
Conservative Leverage And Financial Flexibility
Very low leverage reduces interest burden and financial risk while preserving borrowing capacity for innovation, capacity expansion, and acquisitions. The strong equity base also gives Balchem flexibility to sustain investment and manage operating volatility without relying heavily on external financing.
Broad-based Segment Growth And Differentiated Offerings
Growth across all three reporting segments reduces reliance on a single end market and supports a more resilient business model. Specialty nutrients, delivery systems, and market penetration can deepen customer adoption and reinforce Balchem's position in quality-sensitive nutrition and specialty product applications.
Bears Say
Modest Recent Revenue Growth
The recent top-line pace is modest relative to the company's stronger prior step-up, which may constrain operating leverage and limit the speed of earnings expansion. Sustained profitability therefore depends more heavily on mix, pricing, and execution until broader volume growth accelerates.
Input-cost Pressure Threatens Margins
Persistent raw-material inflation can pressure gross margins when customer price increases do not fully offset costs. Even with strong current profitability, recurring input-cost pressure could reduce earnings conversion and require ongoing pricing actions, efficiency gains, or favorable mix to protect returns.
Ongoing European Antidumping Circumvention
Continued duty circumvention can weaken pricing discipline and delay volume recovery in European monogastrics, limiting the benefit of trade protections. Resolving the issue may require sustained enforcement and commercial effort, while pricing competition could weigh on segment profitability over the medium term.
Balchem News
BCPC FAQ
What is Balchem’s market cap?
When is Balchem’s upcoming earnings report date?
How were Balchem’s earnings last quarter?
Is Balchem overvalued?
Does Balchem pay dividends?
What is Balchem’s EPS estimate?
What happened to Balchem’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Balchem?
What is the TipRanks Smart Score and how is it calculated?
Balchem Stock Smart Score
Company Description
Balchem
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
- Sector
- Basicmaterials
- Industry
- Chemicals - Specialty
- CEO
- Theodore L. Harris
- Employees
- 1,430
- Website
- www.balchem.com
- Address
- 5 Paragon Drive, Montvale, NJ, 07645, US
Balchem (BCPC) Earnings & Revenues
BCPC Company Deck
BCPC Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with record consolidated financial results, growth across all three segments, expanding gross margins, strong cash generation, balance-sheet improvement, continued product and science investment, and confidence in ongoing year-over-year growth. The company also cited challenges including higher input costs, elevated inventory, trade-practice circumvention, oil-price pressure, and normal fourth-quarter seasonality, but these were outweighed by the reported achievements and outlook.
View all MX:BCPC earnings summaries